Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast.
Five of 43 patients (11.6%) with ductal carcinoma in situ of the breast presented with p53 autoantibodies at diagnosis. Three seropositive patients demonstrated tumour sizes of < or = 5 mm. There was no association of p53 autoantibody status with age, clinical presentation, histological subtype, tumour size, grading, p53 immunohistochemistry or hormone receptor status.
Regele
S
S
University of Ulm, Department of Obstetrics and Gynaecology, Germany.
Kohlberger
P
P
Vogl
F D
FD
Böhm
W
W
Kreienberg
R
R
Runnebaum
I B
IB
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000097:blood*; D001943:Breast Neoplasms / Q000276:immunology* / Q000473:pathology; D002278:Carcinoma in Situ / Q000276:immunology*; D018270:Carcinoma, Ductal, Breast / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008875:Middle Aged; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000276:immunology*
D001323:Autoantibodies; D016159:Tumor Suppressor Protein p53